Arnatar Therapeutics, a San Diego biotechnology company working to address high unmet medical needs in cardiometabolic, liver, CNS and kidney diseases, recently launched from stealth with a $52 million Series A funding round. Eight Roads and 3E Bioventures led the funding raise in 2024.
Arnatar Therapeutics is focused on developing RNA-based therapies for underserved diseases. The company is advancing its ART4 therapeutic candidate, which targets Alagille Syndrome by using a unique RNA platform to upregulate a protein responsible for bile duct development.
Alongside the company’s launch, Arnatar announced that the U.S. Food and Drug Administration has granted orphan drug designation and rare pediatric disease designation to its ART4 candidate.
“Receiving both Orphan Drug and Rare Pediatric Disease designations from the FDA highlights the potential of ART4 to address a significant unmet need and meaningfully alter the course of this devastating disease,” Xuehai Liang, Arnatar’s CEO, said in a statement. “We remain committed to advancing ART4 into the clinic as rapidly as possible to bring this potentially transformative therapy to patients and families who currently have no curative treatment options.”
